Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.47 |
| ▸ | SUV39H2 | Q9H5I1 | 13/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6485805 | 0.95 | DRD2 (0.46) | PIM1PIM3PIM2SUV39H2CTSK | |
| SCHEMBL6484872 | 0.94 | BTK (0.49) | PIM1PIM3PIM2SUV39H2CTSK | |
| SCHEMBL31318667 | 0.80 | SUV39H2 (0.51) | PIM1PIM3PIM2SUV39H2CTSK | |
| SCHEMBL28595540 | 0.77 | SYK (0.50) | PIM1PIM3PIM2SUV39H2CTSK | |
| SCHEMBL28595542 | 0.77 | SYK (0.50) | PIM1PIM3PIM2SUV39H2CTSK | |
| SCHEMBL6484073 | 0.76 | MAPT (0.55) | SUV39H2 | |
| SCHEMBL31262679 | 0.75 | JAK3 (0.49) | PIM1PIM3PIM2SUV39H2CTSK | |
| SCHEMBL31262459 | 0.75 | JAK3 (0.49) | PIM1PIM3PIM2SUV39H2CTSK | |
| SCHEMBL6485470 | 0.75 | ALDH1A1 (0.42) | SUV39H2 | |
| SCHEMBL30781462 | 0.74 | PIM1 (0.49) | PIM1PIM3PIM2SUV39H2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969712-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| US-20040044056-A1 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| EP-1342717-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044056-A1 | Benzimidazole derivatives | GPR119, OPRL1, INSR | PIM1 723/4885PIM3 873/4885PIM2 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.